Therefore, the treatment strategy of pyrotinib with metronomic vinorelbine is worthy to be further investigated in large-scale clinical trials for HER2-positive BC patients with LM to improve the prognosis of this population. This evidence concerns the gene ERBB2 and breast cancer.